Cardiovascular disease (CVD), including stroke, is the

Size: px
Start display at page:

Download "Cardiovascular disease (CVD), including stroke, is the"

Transcription

1 Review: Clinical Cardiology: New Frontiers Hypertensive Therapy: Part I Veronica Franco, MD; Suzanne Oparil, MD; Oscar A. Carretero, MD Cardiovascular disease (CVD), including stroke, is the most common cause of death and disability in developed countries, and hypertension is one of the most important modifiable risk factors for these outcomes. 1 The relationship between blood pressure (BP) and CVD mortality is positive, strong, continuous, graded, and predictive, for those with or without coronary heart disease, and it increases with age. 2,3 A meta-analysis of observational studies involving more than 1 million individuals without prior histories of stroke or heart disease carried out by the Prospective Studies Trialists Collaboration demonstrated that death from coronary heart disease and stroke increases continuously and linearly from BP levels as low as 115 mm Hg systolic and 75 mm Hg diastolic. 3 An increment of 20 mm Hg in systolic BP (SBP) or 10 mm Hg in diastolic BP (DBP) in middle-aged and elderly persons is associated with a 2-fold increase in cardiovascular (coronary heart disease and stroke) mortality throughout the entire range of BP (Figure 1). In addition, data from the Framingham Heart Study showed that, when compared with optimum BP (SBP 120 mm Hg and DBP 80 mm Hg), normal BP (SBP 120 to 129 mm Hg or DBP 80 to 84 mm Hg) is associated with a 2- to 4-fold increase in risk of developing hypertension, and high normal BP (SBP 130 to 139 mm Hg or DBP 85 to 89 mm Hg) is associated with a 5-fold increased risk. 4 Hypertension, defined as SBP 140 mm Hg or DBP 90 mm Hg or the use of antihypertensive medications, is a major public health problem, affecting almost 29% of the adult US population, according to the US National Health and Nutrition Examination Survey (NHANES), 5 and 44% of the population in Europe. 6 Importantly, there has been an increase in the prevalence of hypertension in the United States between 1988 to 1991 and 1999 to 2000, a reversal of the previously reported declining trend in hypertension prevalence between 1960 and ,7,8 Although NHANES assessed trends in the cross-sectional prevalence of hypertension in the US population, long-term risk of an individual is best determined by the lifetime risk statistic, which is the probability of developing hypertension during the remaining years of life. Data from the Framingham Heart Study indicated a lifetime risk for developing hypertension of 90% for men and women who were not hypertensive at age 55 or 65 years and survived to age 80 to 85 (Figure 2). 9 Even after adjusting for competing causes of mortality, the remaining lifetime risks of hypertension were 86% to 90% in women and 81% to 83% in men. More than half of the 55-year-old participants developed hypertension within 10 years. Furthermore, the 4-year rates of progression to hypertension in the Framingham cohort were 50% for those 65 years and older with BPs in the 130 to 139 /85 to 89 mm Hg range and 26% for those with BPs in the 120 to 129 /80 to 84 mm Hg range. 4 These rates of hypertension are of great concern, especially because BP control in the United States, although better than in other countries, is still unacceptable: 70% of hypertensives have not achieved their goal ( 140/90 mm Hg overall) BP per the 1999 to 2000 NHANES report. 5 Furthermore, almost 30% of all hypertensives are unaware of their illness, and 42% are not being treated with medication. Control levels are even lower in the European countries, only 8% on average. 6 The relative impact of hypertension treatment strategies in Europe, Canada, and the United States was estimated by using sample surveys conducted in the 1990s. 10 Among persons 35 to 64 years of age, 29% of hypertensives in the United States had their BP controlled at 140/90 mm Hg, compared with 17% in Canada and 10% in Europe. At the 140/90 mm Hg cutpoint, two thirds to three fourths of the hypertensives in Canada and Europe were untreated, compared with slightly less than half in the United States. Undiagnosed, untreated, and uncontrolled hypertension clearly places a significant strain on the healthcare delivery system. Rates of decline of death from CVD have slowed in the past decade, and major complications of hypertension, including heart failure and end-stage renal disease, have actually risen over that time period. 11 In this review, we will summarize the important clinical trials and guidelines for the treatment of hypertension that have been published recently and will outline the most significant developments and key messages in the field that should guide evidence-based medical practice in the coming years. New BP Classification The goal of antihypertensive treatment is to reduce CVD risk and thus morbidity and mortality rates. Because of the new data on lifetime risk of hypertension and the impressive rise From the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham (V.F., S.O.), and the Hypertension and Vascular Research Division, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan (O.A.C.). This is Part I of a 2-part article. Part II will appear in the June 29, 2004, issue of Circulation. Correspondence to Veronica Franco, MD, ZRB 1024, th St South, University of Alabama at Birmingham, Birmingham, AL vfranco@uab.edu (Circulation. 2004;109: ) 2004 American Heart Association, Inc. Circulation is available at DOI: /01.CIR B5 2953

2 2954 Circulation June 22, 2004 Figure 1. Coronary heart disease (A) and stroke (B) mortality rate in each decade of age versus usual BP at the start of that decade. Rates are plotted on a floating absolute scale, and each square has area inversely proportional to the effective variance of the log mortality rate. For DBP, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mm Hg), for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mm Hg). This figure shows that the relationship of coronary heart disease and stroke mortality to usual BP is strong and direct at all ages, with no good evidence of a threshold at any age in the range of usual SBP above 115 mm Hg or of usual DBP above 75 mm Hg. A doubling (ie, proportional, or log) scale has been used for mortality rates, with a 95% CI for each point that reflects the amount of information underlying each risk estimate Reprinted with permission from Elsevier from Lewington et al. 3 in the risk of cardiovascular complications associated with levels of BP previously considered to be normal, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) has introduced a new classification that includes the term prehypertension for those with SBP 120 to 139 mm Hg or DBP 80 to 89 mm Hg (Tables 1 and 2). 12,13 Prehypertension is not a disease category. Rather, it is a designation

3 Franco et al Hypertensive Therapy: Part I 2955 Figure 2. Residual lifetime risk of hypertension in women and men aged 65 years. Cumulative incidence of hypertension in 65-year-old women and men. Data for 65-year-old men in the 1952 to 1975 period are truncated at 15 years because there were few participants in this age category who were followed up beyond this time interval. Reprinted with permission from Vasan et al. 9 chosen to identify individuals at high risk of developing hypertension, so that both patients and healthcare providers are alerted to this risk and encouraged to intervene and prevent or delay hypertension from developing. Individuals who are prehypertensive are not candidates for drug therapy on the basis of their BP and should be firmly advised to practice lifestyle modification to reduce their risk of developing hypertension in the future. However, persons with BPs in the prehypertensive range and comorbid conditions, eg, diabetes or chronic kidney disease, that require intensive BP lowering should be treated aggressively with antihypertensive medications. Specific choices of therapy in this situation should be guided by the nature of the comorbid conditions. In clinical practice, the diagnosis of hypertension should be made on the basis of SBP more often than on DBP: SBP in the population increases with advancing age, whereas DBP tends to plateau or fall after age 60. As a result, knowledge of SBP alone correctly classified the stage of hypertension in 99% of persons 60 years of age or older in the Framingham Heart Study cohort who were not on antihypertensive medication. In contrast, knowledge of DBP alone correctly classified the hypertension stage in only 47% of these persons. 14 Importantly, SBP is a better predictor of events (coronary heart disease, CVD, heart failure, stroke, end-stage renal disease, and all-cause mortality) than is DBP, especially among older persons. 15 Furthermore, SBP is a more difficult therapeutic target than DBP; as will be discussed later, randomized controlled outcome trials of antihypertensive treatment generally have reported much greater success TABLE 1. Changes in Blood Pressure Classification (JNC 6 and 7) JNC 6 Category SBP/DBP JNC 7 Category Optimal 120/80 3 Normal Normal / Prehypertension Borderline /85 89 Hypertension 140/90 3 Hypertension Stage / Stage 1 Stage / Stage 2 Stage 3 180/110 Reproduced with permission from Chobanian et al. 13 ( 90% control rates) for DBP than for SBP (60% to 70% control rates) in moderately high-risk middle-aged and elderly participants. Accordingly, diagnosis, treatment, and control of systolic hypertension deserve particular emphasis in clinical practice, especially in middle-aged and elderly patients (Table 2). The BP classification outlined in JNC 7 is simpler than the one used in JNC 6 16 or in the recent European Society of Hypertension European Society of Cardiology guidelines for the management of hypertension. 17 JNC 7 has combined stage 2 and stage 3 hypertension into a single stage 2 category for several reasons: Stage 3 hypertension (BP 180/110 mm Hg) has become rare in the United States; treatment recommendations for all individuals with BP 20/10 mm Hg above goal are similar because risk is greatly increased in all of these persons based on BP alone; and a simpler BP classification is more user friendly for healthcare providers. This classification does not stratify hypertensives by the presence TABLE 2. Key Messages From JNC 7 In individuals older than age 50 years, SBP is a more important CVD risk factor than DBP. Beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg throughout the BP range. Those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension. Those with SBP 120 to 139 mm Hg or DBP 80 to 89 mm Hg should be considered prehypertensive and require health-promoting lifestyle modifications to prevent a progressive rise in blood pressure and CVD. Thiazide-type diuretics should be initial drug therapy for most, either alone or combined with drugs from other classes. Certain specific high-risk conditions are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, -blockers, calcium channel blockers). Two or more antihypertensive medications will be required to achieve goal BP in most hypertensive patients. For patients with BP 20/10 mm Hg above the BP goal, initiation of therapy using two agents, one of which will usually be a thiazide diuretic, should be considered. Hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. Information derived from Chobanian et al. 12,13

4 2956 Circulation June 22, 2004 TABLE 3. Lifestyle Modifications to Manage Hypertension* Modification Recommendation Approximate Systolic BP Reduction, Range Weight reduction Maintain normal body weight (BMI ) 5 20 mm Hg/10-kg weight loss Adopt DASH diet eating plan Consume a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat 8 14 mm Hg Dietary sodium reduction Reduce dietary sodium intake to no more than 100 meq/l (2.4 g sodium or 6 g sodium chloride) 2 8 mmhg 23,24 Physical activity Moderation of alcohol consumption Engage in regular aerobic physical activity such as brisk walking (at least 30 minutes per day, most days of the week) Limit consumption to no more than 2 drinks per day (1 oz or 30 ml ethanol eg, 24 oz beer, 10 oz wine, or 3 oz 80-proof whiskey ) in most men and no more than 1 drink per day in women and lighter-weight persons 4 9 mmhg 25, mmhg 27 BMI indicates body mass index calculated as weight in kilograms divided by the square of height in meters; DASH, Dietary Approaches to Stop Hypertension. *For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose and time dependent and could be higher for some individuals. Reproduced with permission from Chobanian et al. 12 or absence of risk factors or target-organ damage for the purpose of defining treatment thresholds and goals. Although we recognize the importance of total CVD risk in making treatment recommendations, risk stratification does have major challenges that may limit its use in clinical practice: (1) Many busy practitioners consider the time and effort needed to compile the required data on each patient and to perform the risk stratification calculation to be so excessive that they do not routinely do so, despite recommendations in treatment guidelines. (2) Biological variability is such that risk stratification schemes may yield inexact and incorrect predictions. 18 In the worst case, this would result in erroneous classification of an individual as low risk, leading to inappropriate withholding of treatment. For these reasons, and because elevated BP per se is such a robust CVD risk factor, JNC 7 recommends that all people with hypertension be treated with antihypertensive medications as well as lifestyle modification. The European Society of Hypertension European Society of Cardiology guidelines for the management of hypertension 17 differ in substance from those of JNC 7. 12,13 The European classification of hypertension is complex, including the 3 stages of hypertension (BP 140/90, 160/100, and 180/110) from JNC 6, plus a special class for isolated systolic hypertension (ISH), and the categories of optimal, normal, and high normal BP. The European guidelines classify hypertensive individuals into low, moderate, high, and very high added risk, to indicate an approximate absolute 10-year risk of CVD of 15%, 15% to 20%, 20% to 30%, and 30%, respectively, according to Framingham criteria. 19 Risk stratification is based on the presence or absence of target-organ damage, concomitant risk factors for CVD, history of diabetes, and associated clinical conditions. This classification is used to determine the threshold for antihypertensive drug treatment. According to the European guidelines, some persons with stage 1 or even stage 2 hypertension would be recommended for monitoring and lifestyle modifications only. This represents a substantially less aggressive approach to antihypertensive treatment than that recommended by JNC 7. 12,13 The US and European guidelines also differ in the extent to which they provide specific recommendations to the practitioner for choosing treatments. JNC 7 provides specific recommendations (choice of drugs) for the pharmacological treatment of elevated BP, whereas the European guidelines defer drug choices to the healthcare provider s judgment with consideration of the individual patient s personal, medical, and cultural characteristics. Thresholds and Targets for BP Reduction Therapy On the basis of evidence from multiple clinical trials, JNC 7 recommends that the threshold for pharmacological treatment of hypertension should be BP 140/90 mm Hg, except in the presence of diabetes or chronic kidney disease, in which case prehypertensive persons should be started on appropriate drug therapy, particularly if a trial of lifestyle modification fails to reduce their BP to goal (Table 3 12,13,20 27 ). The BP goal for the general population of hypertensives is 140/ 90 mm Hg; for persons with diabetes or chronic kidney disease, it is 130/80 mm Hg. However, because myocardial infarction, stroke, and other cardiovascular events occur in many individuals with BPs below these (admittedly arbitrary) goals, an ideal BP, based on epidemiological data, would appear to be 115/75 mm Hg or lower. 3 This has prompted many to advocate a go as low as the patient will tolerate strategy of antihypertensive treatment. Expert committees and treatment guidelines have not embraced such a radical approach because evidence from randomized controlled outcome trials with low BP targets is sparse. It is not clear that optimal BP achieved by pharmacological means has a risk profile similar to naturally occurring optimal BP. Furthermore, the risks associated with antihypertensive drug therapy in the high doses needed to reduce BP to optimal levels are uncertain, as is the cost of this approach. Interestingly, data from a number of sources, including the Western Infirmary in Glasgow and NHANES, have shown that hypertensive persons have higher mortality rates than normotensive persons, even when their BP is controlled with antihypertensive medications. The 9-year follow-up data

5 Franco et al Hypertensive Therapy: Part I 2957 from NHANES I, obtained between 1982 and 1984, showed 30% (for women) and 36% (for men) increases in risk of death in persons previously diagnosed as hypertensive and treated with medication, where BP was not elevated on follow-up examination, compared with normotensive persons surveyed. 28 Whether these numbers could be improved with more aggressive BP goals and more modern treatment modalities remains to be determined. The major randomized controlled trial that addressed the issue of BP treatment targets in essential hypertension is the Hypertension Optimal Treatment (HOT) study. 29 HOT evaluated the effects on clinical outcomes of various target DBPs ( 80 mm Hg versus 85 mm Hg versus 90 mm Hg) in hypertensive individuals. In the study as a whole, the lowest incidence of major cardiovascular events occurred at a mean achieved DBP of 82.6 mm Hg, and the lowest risk of cardiovascular mortality occurred at 86.5 mm Hg. However, among the 1501 diabetics enrolled in HOT, there was a 50% reduction in major cardiovascular events in the target group 80 mm Hg compared with the 90 mm Hg group. Achieved DBPs in these two treatment groups in the study as a whole were 81 and 85 mm Hg, respectively, indicating exquisite sensitivity of diabetic persons to small differences in BP. The UK Prospective Diabetes Study Group (UPKDS) carried out a randomized, controlled trial in 1148 hypertensive type 2 diabetics that evaluated the effects of tight BP control (target DBP 85 mm Hg; achieved BP 144/ 82 mm Hg) versus less tight BP control (target DBP 105 mm Hg; achieved BP 154/87 mm Hg) on mortality and CVD outcomes. 30 Tight BP control resulted in statistically significant and clinically important reductions in the risk of death related to diabetes (32%), complications related to diabetes (24%), stroke (44%), and microvascular disease (37%). Thus, both UKPDS and HOT showed major reductions in clinical outcomes associated with relatively small decreases in BP in persons with type 2 diabetes. These data have been used to justify the lower BP goal ( 130/ 80 mm Hg) for hypertensive diabetics proposed in recent guidelines. 12,13,17,31 In addition to diabetes, chronic kidney disease, defined as either reduced excretory function with an estimated glomerular filtration rate 60 ml/min per 1.73 m 2 (approximately corresponding to a creatinine of 1.5 mg/dl in men or 1.3 mg/dl in women) for 3 months or the presence of albuminuria ( 300 mg/d or 200 mg/g creatinine), 12,13,32 is another condition in which prognosis is extremely sensitive to BP. A meta-analysis of randomized controlled trials of antihypertensive treatment in persons with predominantly nondiabetic kidney disease has shown that the lowest risk for disease progression was at SBP levels of 110 to 129 mm Hg; after adjustment for SBP, DBP was not a risk factor. 33 Importantly, the relationship between SBP and risk of kidney disease progression was dependent on urinary protein excretion: At levels of protein excretion 1.0 g/d, risk increased sharply at SBPs 120 to 130 mm Hg, whereas at excretion levels 1.0 g/d, risk did not increase until SBP exceeded 160 mm Hg (Figure 3). The National Kidney Foundation 32 and JNC 7 12,13 Figure 3. Relative risk for kidney disease progression based on current level of SBP and current urine protein excretion. The relative risk for patients with a current urine protein excretion of 1.0 g/d or greater represents 9336 patients (223 events), and the relative risk for patients with a current urine protein excretion 1.0 g/d represents visits (88 events). The reference group for each is defined as SBP 110 to 119 mm Hg. Confidence intervals are truncated, as shown. Results are from a single multivariable model including 2 levels for urine protein excretion, 6 levels for SBP, and the interaction of current SBP and current urine protein excretion. Covariates include assignment to angiotensin-converting enzyme inhibitor versus control group, sex, age, baseline SBP, baseline DBP, baseline urine protein excretion, baseline serum creatinine concentration ( 2.0 or 2.0 mg/dl [ 177 or 177 mol/l]), interaction of baseline serum creatinine and baseline urine protein excretion, interaction of baseline serum creatinine and current urine protein excretion, and study terms. Reprinted with permission from Jafar et al. 33 recommend a goal BP of 130/80 mm Hg for all individuals with chronic kidney disease. Benefit from more intensive versus less intensive antihypertensive therapy on clinical outcomes was shown in the meta-analysis of the Blood Pressure Lowering Treatment Trialists Collaboration, which included a total of individuals enrolled in 4 trials. 34 There was a 23% (95% CI 5 to 37) reduction in the risk of stroke and a 15% (95% CI 5 to 24) reduction in major cardiovascular events with more intensive compared with less intensive treatment. There was not clear evidence of benefit for coronary heart disease (5% [95% CI 11 to 19]), heart failure (16% [95% CI 18 to 41]) or total mortality (4% [95% CI 9 to 16]), but the 95% CIs did not exclude moderate advantages for participants assigned more intensive therapy. Although the level of BP at which disease risks are minimized (the optimal goal BP) cannot be determined from these overviews, the benefits were seen at BP levels substantially lower than those routinely achieved in clinical practice. Acknowledgments This work was supported, in part, by the National Heart, Lung, and Blood Institute grants HL07457 and HL References 1. World Health Organization. World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; Available at: Accessed May 21, 2004.

6 2958 Circulation June 22, Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993; 153: Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. JAMA. 2001;358: Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, JAMA. 2003; 290: Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289: Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the Health and Nutrition Examination Surveys, Hypertension. 1995;26: Burt VL, Whelton P, Rosella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, Hypertension. 1995;25: Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA. 2002;287: Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43: National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; Available at: Accessed May 24, Chobanian AV, Bakris GL, Black HR, et al. Seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 (Express) Report. JAMA. 2003;289: Available at: hypertension/jncintro.htm. Accessed May 24, Chobanian AV, Bakris GL, Black HR, et al. Seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7-Complete Report. Hypertension. 2003; 42: Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension. 1999;34: Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103: JNC 6. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: Mancia G, Rosei A, DeBaker G, et al European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21: McManus RJ, Mant J, Meulendijks CF, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculations tools in general practice: cross sectional study. BMJ. 2002;324: Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health care professionals. Circulation. 1991;83: He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35: The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with highnormal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157: Svetkey LP, Simons-Morton V, Vollmer WM, et al. Effects of dietary patterns on blood pressure: a subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999;159: Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344: Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension. 2000;35: Kelly GA, Kelly KS. Progressive resistance exercise and resting blood pressure. Hypertension. 2000;35: Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure. Ann Intern Med. 2002;136: Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure. Hypertension. 2001;38: Havlik RJ, LaCroix AZ, Kleinman JC, et al. Antihypertensive drug therapy and survival by treatment status in a national survey. Hypertension ;13:I-28 I Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351: Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317: American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27:S15 S National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2004;45: Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition. Ann Intern Med. 2003;139: Turnbull F, Neal B, Algert C, et al. Effects of different blood-pressurelowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists Collaboration. Lancet. 2003;362:

The prevalence of hypertension in a representative

The prevalence of hypertension in a representative CLINICAL STRATEGIES FOR OPTIMAL HYPERTENSION MANAGEMENT Roger S. Blumenthal, MD * ABSTRACT In the United States, approximately 25% of the adult population older than 40 years has hypertension. Americans

More information

w High Blood Pressure Guidelines Create New At-Risk Classification

w High Blood Pressure Guidelines Create New At-Risk Classification Journal of Cardiovascular Nursing Vol. 19, No. 6, pp 357-371 2004 LippincoltWilliams SWilkins, Inc. w High Blood Pressure Guidelines Create New At-Risk Classification Changes in Blood Pressure Classification

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients

Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients Original Paper Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients CME Credit 1 www.lejacq.com/cme John D. Bisognano, MD, PhD; 1 Kevin A. Townsend, MS,

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

A Needs Assessment of Hypertension in Georgia

A Needs Assessment of Hypertension in Georgia A Needs Assessment of Hypertension in Georgia Faye Lopez Mercer University School of Medicine Marylen Rimando Mercer University School of Medicine Harshali Khapekar Mercer University School of Medicine

More information

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario M Paul Anand Consultant Physician, Lady Ratan Tata Medical Centre, M. Karve Road, Cooperage, Mumbai Executive Editor, API Textbook of Medicine Introduction

More information

HYPERTENSION: ARE WE GOING TOO LOW?

HYPERTENSION: ARE WE GOING TOO LOW? HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA

More information

Hypertension is an important global public

Hypertension is an important global public IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card

More information

Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study

Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study EDITORIAL by Nash 1 Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA 2 Divisions of Preventive

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.

Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Item Type Thesis Authors Couch, Christopher Rights Copyright is held by the author.

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Hypertension is a major risk factor for

Hypertension is a major risk factor for OPTIMAL RISK MANAGEMENT OF THE HYPERTENSIVE PATIENT WITH MULTIPLE RISK FACTORS * Keith C. Ferdinand, MD, FACC ABSTRACT To determine the risk of cardiovascular disease in patients with hypertension, it

More information

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST

2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Renal Disease through the Ages: From Childbearing years to Old Age. Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician.

Renal Disease through the Ages: From Childbearing years to Old Age. Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician. Renal Disease through the Ages: From Childbearing years to Old Age Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician. Learning Outcomes: Understand the presentation of renal

More information

Hypertension awareness, treatment, and control

Hypertension awareness, treatment, and control O r i g i n a l P a p e r Prevalence of Self-Reported High Blood Pressure Awareness, Advice Received From Health Professionals, and Actions Taken to Reduce High Blood Pressure Among US Adults Healthstyles

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2015.10.037

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Essential Hypertension Management Considerations By Elaine Lewis, ND

Essential Hypertension Management Considerations By Elaine Lewis, ND Essential Hypertension Management Considerations By Elaine Lewis, ND Elaine Lewis, ND Research Resident, Canadian College of Naturopathic Medicine 1255 Sheppard Avenue East North York, Ontario Back To

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Hypertension JNC 8 (2014)

Hypertension JNC 8 (2014) Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology

More information

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression

More information

Blood Pressure Treatment in 2018

Blood Pressure Treatment in 2018 Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

Hypertension in Adults Across the Age Spectrum

Hypertension in Adults Across the Age Spectrum ORIGINAL CONTRIBUTION Hypertension in Adults Across the Age Spectrum Current Outcomes and Control in the Community Donald M. Lloyd-Jones, MD, ScM Jane C. Evans, DSc Daniel Levy, MD ELDERLY PERSONS ARE

More information

A Study on Prevalence of Hypertension among Chronic Kidney Disease Patients admitted in the Nephrology Department of CAIMS, Karimnagar

A Study on Prevalence of Hypertension among Chronic Kidney Disease Patients admitted in the Nephrology Department of CAIMS, Karimnagar Original Article A Study on Prevalence of Hypertension among Chronic Kidney Disease Patients admitted in the Nephrology Department of CAIMS, Karimnagar Murari Rajendra Prasad 1, Gopal Rao Jogdand 2, Mahesh

More information

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

The Seventh Report of the Joint National Commission

The Seventh Report of the Joint National Commission The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Controlling Hypertension in Primary Care: Hitting a moving target?

Controlling Hypertension in Primary Care: Hitting a moving target? Controlling Hypertension in Primary Care: Hitting a moving target? David J. Hyman, MD,MPH Professor of Medicine and Family & Community Medicine Chief, Section General Medicine Baylor College of Medicine

More information

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Reframe the Paradigm of Hypertension treatment Focus on Diabetes Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification

More information

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016 The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief

More information

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01. NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

Firenze 22 settembre 2007

Firenze 22 settembre 2007 Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non

More information

DEPARTMENT OF GENERAL MEDICINE WELCOMES

DEPARTMENT OF GENERAL MEDICINE WELCOMES DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global

More information

Causes of Poor BP control Rates

Causes of Poor BP control Rates Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular

More information

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,

More information

Health Benefits of Lowering Sodium Intake in the US

Health Benefits of Lowering Sodium Intake in the US Health Benefits of Lowering Sodium Intake in the US Lawrence J Appel, MD, MPH Professor of Medicine, Epidemiology and International Health (Human Nutrition) Director, Welch Center for Prevention, Epidemiology

More information

Study of Serum Uric Acid Level in Hypertension

Study of Serum Uric Acid Level in Hypertension IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 4 Ver. VI (April. 2017), PP 69-73 www.iosrjournals.org Study of Serum Uric Acid Level in Hypertension

More information

Slide notes: This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides,

Slide notes: This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides, 3/23/2016 1 This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides, containing source materials and references. 2 The Framingham,

More information

MANAGEMENT OF HYPERTENSION IN EGYPT AND DEVELOPING COUNTRIES

MANAGEMENT OF HYPERTENSION IN EGYPT AND DEVELOPING COUNTRIES EGYPTIAN HYPERTENSION SOCIETY GUIDELINES MANAGEMENT OF HYPERTENSION IN EGYPT AND DEVELOPING COUNTRIES 2003 EXECUTIVE SUMMARY PREPARED BY M. MOHSEN IBRAHIM, MD PROFESSOR OF CARDIOLOGY- CAIRO UNIVERSITY

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

47 Hypertension in Elderly

47 Hypertension in Elderly 47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

Disclosure. Instead of JNC 8. Proposed Reasons for Delays. Outline 6/10/2013. Member of JNC 8 panel No other disclosures. Daniel T.

Disclosure. Instead of JNC 8. Proposed Reasons for Delays. Outline 6/10/2013. Member of JNC 8 panel No other disclosures. Daniel T. An Update on The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8): The Evidence-Based Process Disclosure Member of JNC 8

More information

HYPERTENSION IS A MAJOR RISK

HYPERTENSION IS A MAJOR RISK ORIGINAL CONTRIBUTION Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 Ihab Hajjar, MD, MS Theodore A. Kotchen, MD Context Prior analyses of National

More information

major public health burden

major public health burden HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing

More information

Hypertension Guidelines 2017

Hypertension Guidelines 2017 Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

Elevated blood pressure (BP) is a major modifiable risk factor

Elevated blood pressure (BP) is a major modifiable risk factor Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women Life Course Analysis Oscar H. Franco, Anna Peeters, Luc Bonneux, Chris de Laet Abstract Limited information

More information

Hypertension in the South-East Asia Region: an overview

Hypertension in the South-East Asia Region: an overview Hypertension in the South-East Asia Region: an overview Anand Krishnan i, Renu Garg ii and Athula Kahandaliyanage iii Abstract Raised blood pressure or hypertension is the single most important risk factor

More information

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Hypertension Update Background

Hypertension Update Background Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

ISPUB.COM. Comparing Weight Reduction and Medications in Treating Mild Hypertension: A Systematic Literature Review. S Hamlin, T Brown BACKGROUND

ISPUB.COM. Comparing Weight Reduction and Medications in Treating Mild Hypertension: A Systematic Literature Review. S Hamlin, T Brown BACKGROUND ISPUB.COM The Internet Journal of Advanced Nursing Practice Volume 3 Number 2 Comparing Weight Reduction and Medications in Treating Mild Hypertension: A Systematic Literature S Hamlin, T Brown Citation

More information

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist

More information

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Hypertension Update. Aaron J. Friedberg, MD

Hypertension Update. Aaron J. Friedberg, MD Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline

More information

THE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)

THE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute

More information

Hypertension Guidelines: International; African,?Kenyan

Hypertension Guidelines: International; African,?Kenyan Hypertension Guidelines: International; African,?Kenyan Elijah N. Ogola University of Nairobi Kenya Cardiac Society Symposium 24 th 25 th February 2017 Eldoret Outline Background Overview of international

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

Blood Pressure LIMBO How Low To Go?

Blood Pressure LIMBO How Low To Go? Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 N OVEMBER 1, 2001 NUMBER 18 IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE

More information

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention,

More information

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama

More information

Clinical Issues Research Implemented April 2010

Clinical Issues Research Implemented April 2010 Hypertension General Management Principals (from the JNC7) In persons older than 50 years, systolic blood pressure greater than 140 mmhg is a much more important cardiovascular disease (CVD) risk factor

More information

Hypertension and diabetic nephropathy

Hypertension and diabetic nephropathy Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney

More information

Touyz, R. M., and Dominiczak, A. F. (2016) Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Hypertension, 67(4), pp. 688-689. There may be differences between this

More information

New Antihypertensive Strategies to Improve Blood Pressure Control

New Antihypertensive Strategies to Improve Blood Pressure Control New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood

More information